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Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset, neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord, leading to paralysis and ultimately to death (Cleveland 1999) . Mutations in the copper/zinc superoxide dismutase 1 (SOD1) gene have been known to cause the inherited form of ALS through an undefined toxic property of the mutant SOD1 protein (Rosen et al. 1993; Gurney et al. 1994) . However, recent studies have demonstrated that neuron-specific expression of the mutant SOD1 did not cause motor neuron disease (Pramatarova et al. 2001; Lino et al. 2002) , suggesting that its toxic effects on motor neurons are indirect. Furthermore, the mutant SOD1 has been shown to inactivate the glial glutamate transporter that plays an important role in maintaining low extracellular glutamate levels (Rothstein et al. 1995; Trotti et al. 1999) . There is substantial evidence to support the notion that an excess of extracellular glutamate may be a critical factor in causing motor neuron disease (Ludolph et al. 2000) . Overstimulation by glutamate results in elevated intracellular calcium levels, which in turn activates intracellular calcium-dependent signaling cascades, eventually leading to neuronal death (Sattler and Tymianski 2000) . The main pathological feature of ALS is characterized by the selective vulnerability of motor neurons. ALS-vulnerable motor neurons are relatively deficient in the calcium-binding proteins, calbindin D-28K and/or parvalbumin, while extraocular motor neurons with abundant levels of these calcium-binding proteins are less likely to degenerate with the disease progression (Alexianu et al. 1994; Siklos et al. 1998; Nimchinsky et al. 2000) .
Thus, the inability to accommodate a large calcium load may be a prerequisite for the selective vulnerability of the motor neurons. Deposits containing calcium have been observed in the spinal motor neurons of ALS patients (Siklos et al. 1996) and also of the animal model (Siklos et al. 1998) , suggesting that the pathogenesis of ALS may be associated with impaired calcium homeostasis in motor neurons. A study showing that overexpression of the calcium binding protein, parvalbumin, delayed the disease onset in a transgenic mouse model of ALS further supports this hypothesis (Beers et al. 2001 ).
Thus, the search for molecular targets involved in impaired calcium homeostasis will help in developing effective therapies aimed at protecting the vulnerable motor neurons in ALS patients.
Cyclin-dependent kinase 5 (Cdk5) is an active enzyme in postmitotic neurons; the activation of Cdk5 requires its association with the neuronal activators, p35 or p39 (Lew et al. 1994; Tsai et al. 1994; Tang et al. 1995) . We have earlier identified the important role of Cdk5 in neuronal migration as well as in brain development (Ohshima et al. 1996 (Ohshima et al. , 1999 (Ohshima et al. , 2002 Tanaka et al. 2001) . Apart from the role of Cdk5 in developing brain, it has also been proposed as a possible target for the downstream molecules causing the neuronal death induced by elevated intracellular calcium. Disturbances in cellular calcium homeostasis induce the cleavage of p35 to its truncated product, p25, through the activation of the calcium-dependent cysteine protease, calpain, which eventually causes the mislocalization of Cdk5 in the cellular compartments and its prolonged activation (Kusakawa et al. 2000; Lee et al. 2000) . This deregulated Cdk5 activity is implicated in neuronal death through both cytoplasmic and nuclear pathways. In the cytoplasm, Cdk5/p25 induces hyperphosphorylation of tau and subsequent cytoskeletal disruptions leading to neuronal death (Patrick et al. 1999; Lee et al. 2000) . In the nucleus, Cdk5/p25 phosphorylates a prosurvival transcription factor, MEF2, and inhibits its anti-apoptotic functions (Gong et al. 2003) . The involvement of p25 in neurodegeneration is further supported by a study showing that transgenic mice expressing p25 specifically in neurons developed a motor neuron disease and paralysis reminiscent of ALS (Bian et al. 2002) .
Moreover, elevated levels of p25 and higher Cdk5 activity have been found in the spinal cord of SOD1 G37R transgenic mice (Nguyen et al. 2001 ). These observations suggest that the deregulation of Cdk5 induced by conversion of p35 to p25 may be involved in the pathogenic mechanism underlying neurodegeneration caused by mutant SOD1. Thus, it is possible that inhibition of the calpain-mediated conversion of p35 to p25 may provide a potential therapeutic approach to slow down the disease progression of ALS.
To test this hypothesis, we generated double transgenic mice in which human SOD1 with a G93A mutation (SOD1 G93A ) was expressed in a p35-null background. We show here that the absence of p35, and hence the lack of p25 generation, did not affect the onset, progression and pathology of motor neuron disease in SOD1 G93A mice, a mouse model of ALS.
Materials and Methods

Materials
Polyclonal antibodies to p35 (C-19) 
Generation of mutant SOD1 transgenic mice lacking p35
The transgenic mice expressing the human SOD1 gene with a G93A mutation (SOD1 G93A ) were obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained as hemizygotes by mating transgenic males with B6/SJL F1 females. This line was originally generated and characterized by Gurney et al. (1994) . p35 mutants were maintained in a C57BL/6 x 129/SvJ hybrid background (Ohshima et al. 2001) . A two-step breeding strategy was employed to obtain the mutant SOD1 mice lacking p35.
Initially, the SOD1 G93A mice were crossed with p35+/-mice to generate the mutant SOD1 mice with a single functional p35 allele. These mice were then crossed with p35+/-mice to generate mutant SOD1 mice, either with or without p35. Thus, these lines were maintained as hemizygotes of the SOD1 G93A transgene. The genotypes of these mice were determined by polymerase chain reaction using DNA extracted from the tail (Gurney et al. 1994; Ohshima et al. 2001) . Mice were housed under a 12 h light/ 12 h dark cycle. All care was given in compliance with National Institutes of Health guidelines on the use of laboratory and experimental animals.
Preparation of the spinal cord extracts
Lumbar spinal cord lysates were prepared in a lysis buffer consisting of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin and 1 µg/ml leupeptin. To examine the phosphorylation state of tau, phosphatase inhibitors (phosphatase inhibitor cocktail I and II, SIGMA, St. Louis, MO) were further added in the lysis buffer. Following a 30-min incubation on ice, insoluble material was removed by centrifugation at 4°C, and the protein concentration of the supernatant was determined using the BCA protein assay (Pierce, Rockford, IL). Fractionation of spinal cord lysates into a cytosolic fraction and a membrane fraction was performed as previously reported (Kusakawa et al. 2000) .
Briefly, the lumbar spinal cords were homogenated in 10 volumes of HEPES buffer (20 mM HEPES, pH 7.4, 5 mM KCl, 1.5 mM MgCl 2 , 1 mM dithiothreitol, 1 mM EGTA) at 4°C and then centrifuged at 10,000 X g for 15 min. The resulting supernatant was further centrifuged at 100,000 X g for 60 min. The supernatants were collected as a cytosolic fraction. The remaining pellets were resuspended in HEPES buffer containing 150 mM NaCl and 1% Triton X-100 and used as a membrane fraction.
Western blot analysis
Equal amounts of protein (20 µg) were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) before being transferred onto a nitrocellulose membrane. The membranes were blocked in 1× PBS containing 5% skim milk and 0.05% Tween 20, and incubated with primary antibodies overnight at 4°C. The primary antibodies used were as follows: anti-p35 (1:1,000), anti-Cdk5 (1:1,000), antihSOD1 (1:4,000), AT-8 (diluted to 5 µg/ml), Tau-1 (1:5,000), Tau-5 (1:6,000) and anti-α-tubulin (1:4,000) antibodies. Incubation with peroxidase-conjugated anti-mouse or rabbit IgG (1:10,000) was performed at room temperature for 60 min. A signal was detected by enhanced chemiluminescence (Pierce, Rockford, IL) and relative optical densities of the bands were quantified using an image analysis system with NIH Image software, version 1.62. To determine the p35 and p25 protein levels, the data obtained with the p35 antibody (C-19) were normalized to α-tubulin levels on the stripped and reprobed membranes. For reuse, the membranes were stripped for 30 min at 50°C in 63 mM Tris-HCl (pH 6.8) containing 100 mM 2-mercaptoethanol and 2% SDS.
Cdk5 kinase activity assay
Lumbar spinal cord lysates were prepared with the same lysis buffer except with a NaCl concentration of 50 mM, to allow Cdk5 association with p35 and p39 as previously described (Takahashi et al. 2003) . The lysates were immunoprecipitated with anti-Cdk5 (C-8) antibody. The Cdk5 immunoprecipitates were prepared by incubation of 300 µl of the lysate (corresponding to 300 µg of protein) with anti-Cdk5 antibody (3 µg) overnight at 4°C followed by further incubation with 25 µl of Protein A-Agarose beads (50% slurry in lysis buffer; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 3 hours at 4°C. The immunoprecipitates were washed twice with the lysis buffer and twice with a kinase buffer consisting of 50 mM Tris-HCl (pH 7.4), 5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA and 1 mM dithiothreitol, and resuspended in 60 µl of the kinase buffer. Kinase activity assays were performed using either histone H1 or bacterially-expressed human tau as a substrate as described previously (Takahashi et al. 2003) . Briefly, a total volume of 50 µl of kinase assay mixture was used, containing 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 5 mM MgCl 2 , 0.5 mM microcystin LR, 10 µl of the immunoprecipitate and either 10 µg of histone H1 or 5 µg of tau. The phosphorylation reaction was initiated by the addition of 0.1 mM [γ-32 P] ATP and incubated at 30°C for 60 min. The reaction was stopped by the addition of SDS-PAGE sample buffer and boiled immediately for 5 min. Samples were separated by SDS-PAGE on a 15%
polyacrylamide gel, and autoradiography was performed to detect the phosphorylation of histone H1 or tau.
Determination of disease onset and progression
A Rotarod (Rota-Rod for Mice 7650; Ugo Basile, Comerio, Italy) was used to evaluate motor function. All mice were initially trained for a total of ~20 min on the rotating rod at four different speeds (5, 10, 15 and 20 rpm; 5 min per each speed) everyday for 3 days.
Performance was then determined at intervals of 3-4 days before the disease onset and thereafter at intervals of 10 days throughout the disease progression, and the time each mouse remained on the rotating rod at the different speeds was registered. The onset of disease was defined as the age at which the mouse could not remain on the rotarod for 7
min at a speed of 20 rpm, as described previously . If the mouse remained on the rod for >7 min, the test was completed and scored as 7 min. Terminal illness was defined by either the inability of a mouse to right itself within 10 sec when left on its back or the inability to reach for food or water as described previously (Subramaniam et al. 2002) .
Immunohistochemistry
The SOD1 G93A mice, either with or without p35, were studied at two different disease To compare the number of motor neurons in the lumbar spinal cord of SOD1 G93A mice, either with or without p35, we counted neurons on the ChAT-immunostained sections spanning the lumbar enlargement in each group, as previously described . For each mouse, at least 20 sections, collected at every seventh serial section (14 µm), were subjected to counting. The results were expressed as the number of motor neurons per anterior horn.
Results
Generation and characterization of SOD1 G93A transgenic mice lacking p35
To examine the possible relevance of Cdk5 to the pathogenesis of ALS, we generated SOD1 G93A transgenic mice lacking the neuronal Cdk5 activator, p35, by crossing the mutant SOD1 transgenic mice with p35+/-mice. Our breeding strategy maintained the SOD1 G93A transgene in a hemizygous state and allowed us to examine the SOD1 G93A mice, in the presence or absence of p35, as well as their littermate controls (wild-type and p35-/-mice). We first examined the protein levels of mutant SOD1 and Cdk5 in the lumbar spinal cord of these mice at the age of 80 days, by which time none of them had developed any motor impairment. The amount of mutant SOD1 in the lumbar spinal cord of SOD1 G93A mice was not altered by a lack of p35 (Fig. 1a) . Moreover, there was no difference in the amount of Cdk5 protein in these mice. So, we examined the effects of the presence or absence of p35 on the Cdk5 kinase activity, using Cdk5
immunoprecipitates from the lumbar spinal cord extracts. The SOD1 G93A ; p35-/-mice showed a significant reduction of Cdk5 activity (less than 20%) as compared to SOD1 G93A ; p35+/+ mice (Fig.1b) . In contrast, there was no difference in Cdk5 kinase activity for histone H1 between p35-/-and SOD1
G93A
; p35-/-mice (Fig. 1b) , suggesting that Cdk5/p39 activity was unaffected by the mutant SOD1. We did not detect an increased conversion of p35 to p25 as well as higher Cdk5 activity in the SOD1 G93A mice at the age of 80 days as compared to the age-matched wild-type littermates ( Fig. 1a and b), in contrast to a previous report that demonstrated these changes in SOD1 G37R mice at the end-stage of disease (Nguyen et al. 2001) . Because our results were obtained from the 80-day-old mice, we wondered whether the use of the pre-symptomatic mice failed to detect the deregulation of Cdk5. Therefore, we examined the conversion of p35 to p25
and Cdk5 activity with the disease progression, using the SOD1 G93A mice at the different stages of disease and their age-matched wild-type littermates. Most of the mutant SOD1 mice developed the motor impairment by 100 days of age and died by 130 days of age (Table 1) . Thus, we selected three different disease stages based on rotarod performance tests: day 80 as the pre-symptomatic stage, day 100 as the symptomatic stage and day 120 as the end-stage of disease. The levels of p35 protein gradually decreased in the SOD1 G93A mice with the disease progression, while the p25 levels decreased to a lesser extent (Fig. 2a, b and c) . Consequently, the ratio of p25 to p35 seemed to increase in the SOD1 G93A mice at 120 days of age (Fig. 2d ), while this change was not statistically significant (p = 0.23). Cdk5 kinase activity significantly decreased in the SOD1 G93A mice with the disease progression, which resulted in a 60% reduction in the activity at the endstage of disease (120 days of age) as compared to the age-matched wild-type littermates ( Fig. 2e and f) . This change of Cdk5 activity in SOD1 G93A mice seemed to occur in parallel with the progressive decrease in the amount of p35, and thus p25 protein.
The subcellular localization of p35 has been known to be different from that of p25: p35 is associated with membranes, while p25 is present in a cytosolic fraction (Patrick et al. 1999; Kusakawa et al. 2000) . Therefore, we have further analyzed the amount of p35 and p25 proteins in the fractionated spinal cord lysates from SOD1 G93A mice at 120 days of age and their age-matched wild-type littermates. As previously reported, p35 was more abundant in the membrane fraction, while p25 remained in the supernatant as a soluble form. The decreased levels of p35 and p25 proteins in the SOD1 G93A mice was pronounced in the membrane fraction and in the cytosolic fraction, respectively, further confirming that the levels of p35 and p25 proteins decreased in spinal cord of SOD1 G93A mice (Fig. 2g) . Cdk5 kinase activity in the fractionated lysates was measured using either histone H1 or tau as a substrate, and was found to decrease in the SOD1 G93A mice as compared to that in the wild-type littermates (Fig. 2h) . It was noteworthy that Cdk5 in the cytosolic fraction from SOD1 G93A mice had a decreased ability to phosphorylate tau, because the deregulation of Cdk5 by p25 has been known to promote the hyperphosphorylation of tau (Patrick et al. 1999) . These results indicated that neurodegeneration caused by the SOD1 G93A mutant protein resulted in a significant reduction of Cdk5 activity and in a progressive decrease of p35 and p25 proteins.
p35-independent development of motor deficits in SOD1 G93A transgenic mice
To examine the effects of Cdk5/p35 or Cdk5/p25 on the phenotype of motor neuron disease in mutant SOD1 mice, we determined the age of disease onset and the life span of SOD1 G93A mice in the presence or absence of p35. Because the mutant SOD1 mice lacking p35 were generated with a mixed genetic background by crossing the mutant SOD1 mice (B6/SJL background) with p35 mutants (C57BL/6 x 129/SvJ hybrid background), analysis of the motor functions was carried out using a large number of littermate mice (SOD1
G93A
; p35+/+ mice, n=17 and SOD1 G93A ; p35-/-mice, n=15). The onset of disease (Table 1) was not significantly different in the SOD1 G93A ; p35-/-mice as compared to the SOD1 G93A ; p35+/+ mice (Fig. 3a) . In addition, the mean life span of the SOD1 G93A ; p35-/-mice (Table 1 ) was similar to that of the SOD1 G93A ; p35+/+ mice (Fig.   3b ). However, it appeared that between 120 and 130 days of age, the probability of survival dropped 60% in SOD1
; p35-/-mice, but only 24% in SOD1 G93A ; p35+/+ mice (Fig. 3b) . This observation suggested that the loss of Cdk5/p35 activity might affect the survival of SOD1 G93A mice at the end-stage of disease (120 days of age) when the Cdk5 activity in SOD1 G93A mice had dropped to approximately 60% of that in wild-type mice.
To further determine how the presence or absence of p35 affects motor deterioration in the mutant SOD1 mice, we tested the performance of these mice on a rotarod every 10 days beginning at 70 days of age (pre-symptomatic stage) and continued the tests until most of the mice could no longer remain on the rod at 120 days of age. These tests revealed that the absence of p35 did not affect the disease progression in the mutant SOD1 mice (Fig. 4) . Furthermore, we did not find any motor impairment in rotarod performance of their littermate controls, wild-type (n=14) and p35-/-mice (n=12) (data not shown). Taken together, these results suggest that Cdk5/p35 or Cdk5/p25 has no impact on the onset and progression of motor neuron disease in SOD1 G93A mice, while the life span of SOD1 G93A mice may be affected to some extent by p35 deficiency.
Pathological lesions in SOD1
G93A mice remain unaltered in the absence of p35.
To further examine the features of motor neuron disease in SOD1 G93A mice, either with or without p35, we carried out neuropathological analysis of these mice as well as their wild-type and p35-/-littermates. At the ages of 80 days (pre-symptomatic stage) and 120 days (end-stage of disease), three animals from each genotype were sacrificed and the lumbar spinal cords were histopathologically evaluated. In order to label the motor neurons in the spinal cord specifically, the sections were immunostained for choline acetyltransferase (ChAT) (Fig. 5) . Labeling was restricted to large neurons in the anterior horn of the spinal cord, and the pattern of ChAT-immunoreactivity was similar to that observed by retrograde labeling of motor neurons through the peripheral nerve (Takahashi et al. 1999) . There was no difference in cell number of the ChATimmunoreactive neurons from wild-type and p35-/-mice at the ages of 80 and 120 days (Fig. 5 ). However, a significant reduction in the number of the ChAT-immunoreactive neurons was observed in the mutant SOD1 mice, irrespective of the presence or absence of p35, as the disease progressed from the pre-symptomatic stage (80 days of age) to the end-stage of disease (120 days of age) (Fig. 5 ).
Abnormal cytoplasmic immunoreactivities for phosphorylated neurofilaments and ubiquitin have been known to be histopathological hallmarks of ALS. Therefore, we examined these abnormalities in 120-day-old mice by immunostaining the sections with anti-phosphorylated neurofilament and anti-ubiquitin antibodies (Fig. 6) . In wild-type and p35-/-mice, immunoreactivity for phosphorylated neurofilaments was mainly present within the neuropils of the spinal cord ( Fig. 6a and c) , while the numerous motor neurons in the mutant SOD1 mice exhibited a strong immunoreactivity for phosphorylated neurofilaments in the cell bodies and in the axon hillocks, irrespective of the presence or absence of p35 ( Fig. 6b and d) . Weak immunoreactivity for ubiquitin was observed in the cytoplasm of motor neurons from wild-type and p35-/-mice ( Fig. 6e and g ). In the mutant SOD1 mice, either with or without p35, strong immunoreactivity for ubiquitin was observed in the cytoplasm of motor neurons and in the neurites ( Fig. 6f and h) .
Thus, the aggregation of phosphorylated neurofilaments and ubiquitinated deposits observed in spinal motor neurons from the mutant SOD1 mice were not altered by the absence of p35. These results indicated that the histopathological lesions in SOD1 G93A mice were independent of the presence or absence of p35 and p25 proteins.
We further examined the phosphorylation state of tau in the spinal cord lysates of 120-day-old SOD1 G93A mice, either with or without p35, as well as their wild-type and p35-/-littermates, because hyperphosphorylation of tau has been found in another ALS model animal, SOD1 G37R mice (Nguyen et al. 2001) . We used an AT-8 antibody that recognizes tau only when Ser-202 and Thr-205 are phosphorylated (Biernat et al. 1992) , and a Tau-1 antibody that recognizes a dephosphorylated epitope of tau at amino acid 191-224 (Iqbal and Grunke-Iqbal 1995) . To determine the total tau levels, the phosphorylation-independent monoclonal antibody, Tau-5, was used (LoPresti et al. 1995) . No AT-8 immunoreactivity was found in the samples from wild-type and SOD1 G93A mice as well as from p35-/-and SOD1
G93A
; p35-/-mice, while the strong AT-8 immunoreactivity was detected in samples from E18.5 wild-type embryos which served as a positive control (Fig. 7) . The signal intensity for Tau-1 immunoreactivity decreased in samples from SOD1 G93A mice, either with or without p35, as compared to those from the wild-type and p35-/-mice (Fig. 7) . However, the decreased levels of Tau-1 immunoreactivity in samples from SOD1 G93A ; p35+/+ and SOD1 G93A ; p35-/-mice were accompanied by the reduction of total tau levels ( Fig. 7) , which may reflect the loss of spinal motor neurons observed in these animals at the end-stage of disease. In the light of a previous observation that tau is hyperphosphorylated in spinal cord of SOD1 G37R mice (Nguyen et al. 2001) , our results suggest that the phosphorylation state of tau in mutant SOD1 mice may be differentially affected by the specific mutations of the SOD1 gene.
Discussion
Transgenic mice expressing mutant SOD1 develop a dominantly inherited adultonset paralytic disorder that replicates many of the clinical and pathological features of familial ALS (Gurney et al. 1994) . Existence of this animal model with a time lag between the disease onset and death allowed us to test the hypotheses that the deregulation of Cdk5 induced by conversion of p35 to p25 may be involved in the pathogenesis of mutant SOD1-linked ALS, and that Cdk5/p35 may be a possible therapeutic target to slow down the disease progression. We generated the SOD1 G93A mice lacking p35 to determine the effects of the absence of p35, and hence the subsequent inhibition of p25 generation, on the clinical and pathological features of the mutant SOD1 mice. We found that the p35 deficiency had no effects on the onset and progression of the motor neuron disease, while the absence of p35 resulted in a significant reduction of Cdk5 activity in the spinal cord of the mutant SOD1 mice.
Furthermore, the pathological analysis of the mutant SOD1 mice, in the presence or absence of p35, indicated no differences in the progression of motor neuron loss and in the altered immunoreactivities to ubiquitin and phosphorylated neurofilaments. These results provide a compelling evidence that Cdk5/p35 and Cdk5/p25 do not participate in the pathogenesis of motor neuron degeneration caused by the mutant SOD1 (SOD1 G93A ).
Thus, inhibition of the calpain-mediated conversion of p35 to p25 is unlikely to confer protective effects on motor neuron disease in mutant SOD1-linked ALS.
We also found that the levels of p35 protein in the spinal cord of SOD1 G93A mice gradually decreased with the disease progression, while the p25 levels decreased to a lesser extent. These changes seemed to occur in parallel with a progressive loss of spinal motor neurons and resulted in a significant reduction of Cdk5 activity. This is in contrast to a previous report that demonstrated the increased levels of p25 and higher Cdk5 activity in SOD1 G37R mice (Nguyen et al. 2001) . The reasons for this discrepancy are not apparent because both studies used the mutant SOD1 mice at the end stage of disease. It is unlikely that the methodological differences may contribute to this discrepancy because we used the same procedures to those used by Nguyen et al. (2001) . One factor that might be responsible for this discrepancy is the choice of SOD1 mutant strains (SOD1 G93A vs. SOD1 G37R mice). The clinical and pathological features of motor neuron disease in mutant SOD1 mice are likely to depend upon the expression levels of the mutant SOD1 as well as the specific mutation in the SOD1 gene. A higher level of Cdk5 activity has been found in a SOD1 G37R mouse line expressing a higher level of the mutant SOD1, which showed a shorter life span (average 24 weeks) relative to another line expressing a lower level of the mutant SOD1 (average life span, 52 weeks). In contrast, Cdk5 kinase activity in the SOD1 G93A mice (average life span, 18 weeks) used in this study significantly decreased with the disease progression, resulting in a 60% reduction in the activity at the end-stage of disease as compared to the non-transgenic littermates.
In addition to the differences in clinical features between the SOD1 G93A and SOD1 G37R mice, the pathological features are also not similar between these strains: astrocytosis in presymptomatic mice was observed in SOD1 G37R mice, but not in SOD1 G93A mice (Tu et al. 1996; Wong et al. 1995) , and the aggregation of cytoplasmic proteins observed in SOD1 G93A mice was very rare in SOD1 G37R mice (Watanabe et al. 2001) . Furthermore, we found no immunoreactivity for phosphorylated tau at serine-199 and threonine-205 in the spinal cord extracts of SOD1 G93A mice, while hyperphosphorylation of tau at these sites has been found in the spinal motor neurons of SOD1 G37R mice (Nguyen et al. 2001) .
Another difference was the propensity of neurons in these mouse lines to convert p35 to p25. The p25 protein level was increased in spinal cord extracts of SOD1 G37R mice, while it was decreased in those of SOD1 G93A mice, resulting in the reduced ability of Cdk5 to phosphorylate tau. Thus, the overexpression of SOD1 G93A or SOD1 G37R may have different effects on the Cdk5 pathway. However, our findings indicating that the absence of p35, and hence the subsequent inhibition of p25 generation, had no effect on the clinical and pathological features of motor neuron disease linked to mutant SOD1, suggest that Cdk5 deregulation is unlikely to contribute to ALS-like disease progression in mutant SOD1 transgenic mice.
The generation of p25 from p35 through the activation of calpain, is induced by various neurotoxic insults such as ischemia, oxidative stress or amyloid β-peptide (Kusakawa et al. 2000; Lee et al. 2000) . Amyloid β-peptide is a primary constituent of the amyloid plaques in Alzheimer's disease brain that have been suggested to trigger the cascade of molecular events leading to neurodegeneration (Harkany et al. 2000; Masliah and Rockenstein 2000) . Interestingly, inhibition of either Cdk5 or calpain activities has been reported to prevent amyloid β-peptide induced neuronal death (Alvarez et al. 1999; Lee et al. 2000) . Furthermore, upregulation of the p35 conversion to p25, has been found in brains of Alzheimer's disease patients (Patrick et al. 1999 ). These observations suggested that alteration in the regulatory pattern of Cdk5 might play a key role in the sequence of molecular events leading to neurodegeneration in Alzheimer's disease.
However, postmortem cleavage of p35 to p25 has been known to proceed within a relatively short time (Taniguchi et al. 2001) . Therefore, it still remains to be determined whether the increased conversion of p35 to p25 is a postmortem event or an in vivo condition in Alzheimer's disease brains. Transgenic mouse models that overexpress mutant amyloid precursor protein under the regulatory control of neuronal promoters have been reported to exhibit Alzheimer's disease-like neuropathology (Masliah and Rockenstein 2000) . Analysis of these transgenic mice bred in a p35-null background, as we did here in an animal model of ALS, will provide important insights regarding the involvement of Cdk5 deregulation in the pathogenesis of Alzheimer's disease.
Generation of genetically altered animal models for neurodegenerative diseases and their careful analysis will be a helpful strategy not only for determining the precise pathogenic mechanism underlying these diseases, but also for identifying the effective therapeutic approaches to treat the patients with these debilitating diseases. Quantitative results indicate the relative Cdk5 kinase activity, expressed as a percentage of the value for wild-type mice and shown as the mean ± S.E. from three independent experiments. These data were analyzed using the unpaired, two-tailed Student's t test and considered to be significantly different when p < 0.05 (*). shown as the mean ± S.E. from three independent experiments. These data were analyzed using the unpaired, two-tailed Student's t test and considered to be significantly different when p < 0.05 (*). (g) Spinal cord lysates from SOD1 G93A mice and their nontransgenic littermates at the age of 120 days were fractionated into the supernatants as a cytoplasmic fraction and the pellets as a membrane fraction by ultracentrifugation at 100,000 X g for 60 min, as described in Materials and Methods. The fractionated samples were examined by Western blotting with anti-p35 and anti-α-tubulin antibodies.
(h) Cdk5 kinase activities in the fractionated samples were examined using either histone H1 or tau as a substrate. ; p35+/+, p35-/-and SOD1 G93A ; p35-/-mice, while the strong AT-8 immunoreactivity was detected in samples from wild-type embryos. Note that the reduced Tau-1 immunoreactivity in samples from SOD1 G93A mice, either with or without p35, was accompanied by the decreased levels of total tau. Note: Data were analyzed using the unpaired, two-tailed Student's t test and expressed as the mean ± S.E. 
